TriSalus Life Sciences, the Westminster, Colorado developer of pressure-enabled drug delivery systems for cancer treatment, has agreed to merge with an undisclosed special purpose acquisition company in a transaction expected to close second quarter 2025. The deal structure provides $150 million in gross proceeds to fund Phase II and Phase III trials of its Pancreatic Artery Infusion platform, which uses controlled pressure to push chemotherapy directly into solid tumors through arterial catheters.
The SPAC vehicle remains unnamed pending SEC filing clearance, but the merger represents a 42% discount to TriSalus's last private valuation of $680 million from its 2022 Series C round led by Deerfield Management and RTW Investments. The company has raised $287 million across four venture rounds since 2018, with most recent capital deployed toward completing enrollment in its PERIO-03 trial for pancreatic ductal adenocarcinoma, a cancer with median survival under twelve months and limited treatment options beyond systemic chemotherapy.
The timing reflects tightening in late-stage biotech venture, where $4.2 billion deployed in Q4 2024 marked a 31% decline from the prior quarter, according to PitchBook data. TriSalus's technology—essentially precision drug delivery through pressure modulation rather than novel molecules—sits in a category that generates clinical interest but struggles to attract the same venture multiples as platform plays in cell therapy or antibody-drug conjugates. The SPAC route gives the company access to public-market liquidity without the eighteen-month roadshow typical of traditional IPOs, and locks in capital before the FDA's expected mid-2025 decision on expedited pathways for drug delivery devices.
The Pancreatic Artery Infusion system delivers gemcitabine and nab-paclitaxel—already-approved chemotherapies—under controlled arterial pressure to increase tumor penetration while reducing systemic toxicity. Early-stage data showed 68% objective response rates in locally advanced pancreatic cancer patients versus 31% for standard infusion, though the company has yet to report progression-free survival or overall survival endpoints from its pivotal trials. The platform's appeal lies in compatibility with existing oncology drugs, avoiding the molecule-development risk that has sunk competitors like Halozyme and delayed approvals for others in the delivery-device category.
Operators should track three events: the SPAC's Form S-4 filing expected within thirty days, which will reveal pipe investors and dilution terms; interim data from the PERIO-03 trial scheduled for the American Society of Clinical Oncology meeting in June 2025; and FDA feedback on the company's Breakthrough Device designation application, which could shorten approval timelines by six to nine months if granted. The merger also includes a $40 million backstop from existing investors, signaling conviction despite the down-round structure.
The deal closes the gap between TriSalus and its closest public comp, Boston Scientific's interventional oncology division, which generated $1.1 billion in 2024 revenue from arterial embolization devices but lacks TriSalus's pressure-modulation chemistry.